

# NEWS RELEASE



November 29, 2021

## **Nippon Shinyaku Implements VILTEPSO<sup>®</sup> Managed Access Program**

**Kyoto, Japan, November 29, 2021** – Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai) announces that it has implemented a Managed Access Program for VILTEPSO<sup>®</sup> (viltolarsen) for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping therapy.

DMD is a progressive muscular dystrophy that causes progressive weakness of skeletal, cardiac, and pulmonary muscles due to a gene mutation in the dystrophin gene. There are many types of genetic mutations that can cause DMD. VILTEPSO<sup>®</sup> is indicated for patients with DMD mutations that are amenable to exon 53 skipping.

The Managed Access Program will enable early access to VILTEPSO<sup>®</sup> for eligible patients in countries where it is not commercially available. VILTEPSO<sup>®</sup> is currently only approved in the US and Japan.

Nippon Shinyaku has signed an exclusive agreement with Clinigen Group plc (AIM: CLIN, 'Clinigen') to implement the Managed Access Program. Under the terms of the agreement, Clinigen will manage key elements of the program including regulatory oversight, logistics and access management.

Healthcare professionals can obtain details about the VILTEPSO<sup>®</sup> Program by calling the customer service team at +44 1932 824001 or emailing [medicineaccess@clinigengroup.com](mailto:medicineaccess@clinigengroup.com).

Patients seeking medical information should contact their physician.

### **About Nippon Shinyaku**

Our mission is to help people lead healthier and happier lives. Through creating unique medicines that will bring hope to patients and families struggling with illness, we aim to be an organization trusted by the community.

Please visit our website (<https://www.nippon-shinyaku.co.jp/english/>) for products or detailed information.

### **About Clinigen Group**

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products company focused on providing ethical access to medicines. Its' mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 20,000 healthcare professionals across more than 120 countries.

For more information on Clinigen, please visit <http://www.clinigen.com>